• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Johnson & Johnson Vision launches new contact lenses

Johnson & Johnson Vision launches new contact lenses

September 12, 2022 By Sean Whooley

Johnson & Johnson Vision logoJohnson & Johnson Vision announced today that it launched its new Acuvue Oasys Max 1-day contact lenses and multifocal lenses for presbyopia.

The lenses feature Johnson & Johnson’s TearStable technology for tear-film stability and locking in moisture. They also offer the OptiBlue light filter for filtering blue-violet to reduce light scatter for visual clarity.

Johnson & Johnson said in a news release that the Acuvue Oasys Max 1-day lenses block 99.9% of UVA rays and 100% of UVB rays.

“Life has changed, post-pandemic. With more time spent on digital devices, we designed these contact lenses by listening to patients and eye care professionals’ feedback to address lifestyle requirements and help prevent dry and tired eyes from becoming normalized,” said John Buch, senior principal research optometrist, Johnson & Johnson Vision. “Our new Acuvue Oasys Max 1-day contact lenses help reduce discomfort by providing visual clarity with new technologies to filter blue-violet light, which comes from many sources, including digital screens and travels in short wavelengths and scatters more which can lead to eye discomfort and quality of vision.”

More about the new contact lenses

The multifocal lenses offer clear vision at all distances and in all lighting conditions, the company said. They feature pupil-optimized design technology aimed at tailoring 100% of parameters to pupil size variations across both age and refraction. Johnson & Johnson Vision said this technology is available across all Acuvue multifocal contact lenses.

Acuvue Oasys Max 1-day and multifocal lenses received FDA clearance, Health Canada approval and CE mark approval earlier this year.

“I’ve witnessed more patients facing symptoms related to a destabilized tear film such as dryness and inconsistent vision due to our increasingly digital lifestyles. It’s important for all contact lens users to have the latest innovative treatment options available to help address comfort and clarity to meet their lifestyle requirements,” said Luis Rojas, co-founder of DeNovo Eye. “Acuvue Oasys 1-day uses innovative technology, designed to maximize tear film stability and reduce light scatter to maintain increased visual clarity and all-day comfort.”

Filed Under: Business/Financial News, Featured, News Well, Optical/Ophthalmic Tagged With: Johnson & Johnson, Johnson & Johnson Vision

More recent news

  • Former Medtronic RDN leader joins Teleflex
  • CMR Surgical CEO outlines the path forward for Stryker’s robotics partnership
  • Stryker earns FDA clearance for new bone and soft tissue removal platform
  • MiniMed completes split from Medtronic
  • GE HealthCare’s on-site cyclotron for PET agent production claims CE Mark

About Sean Whooley

Sean Whooley is a senior editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy